The large prospective study published in the Journal of the National Cancer Institute builds on the 2011 results, which suggest that high omega-3 status may be linked to prostate cancer.
Under the direction of lead author Dr. Alan Kristal of the Fred Hutchinson Cancer Research Center, USA, the new follow-up study confirms the results of the previous research by analyzing data from a large European population study and finding that high blood levels of long chain omega 3 polyunsaturated fatty acids (PUFAs) were with an um 71% higher risk of developing high-grade prostate cancer.
The study also found a 44% increase in the risk of low-grade prostate cancer and a 43% increase in the risk of all prostate cancers.
“We have again shown that supplement use can be harmful,” said Kristal, who added that the results of both the 2011 study and recent research are surprising given that omega-3s are widely believed to be one Host have beneficial health effects due to their anti-inflammatory properties.
“The consistency of these results suggests that these fatty acids are involved in prostate tumor development, and recommendations for increasing intake of long-chain omega-3s, particularly through supplementation, should consider the potential risks,” the team said.
“It is important that we were able to repeat our results from 2011 and have confirmed that marine omega-3 fatty acids play a role in the occurrence of prostate cancer,” said the corresponding author Dr. Theodore Brasky of the Ohio State University Comprehensive Cancer Center – and lead author of the 2011 study.
“It is important to note, however, that these results do not answer the question of whether omega-3 fatty acids play a detrimental role in the prognosis of prostate cancer,” he said.
The new prospective study analyzed data and samples from men who participated in the Selenium and Vitamin E Cancer Prevention Study (SELECT), a large randomized, placebo-controlled study in Europe to test whether selenium and vitamin E were either alone or in combination, reduced prostate cancer risk.
Using data from the SELECT study, the team analyzed the omega-3 status of blood plasma for 834 men diagnosed with prostate cancer – 156 of whom were high-grade cancer – and a comparison group of 1,393 men who happened to be out of the 35,500 Participants were selected.
Compared to men with the lowest blood plasma levels of long-chain omega-3 polyunsaturated fatty acids (PUFA), those with the highest concentrations had an increased risk of low-grade (44% increased risk), high-grade (71% increased risk), and total prostate cancer (43 % higher risk).
The team added that these associations were “similar” for individual long-chain omega-3s – and found that higher levels of linoleic acid (omega-6) were associated with a decreased risk of low-grade and total prostate cancer; but noting that there was no dose response.
The authors found that their results did not make it clear why high levels of omega-3 fatty acids might increase prostate cancer risk. However, they suggested that the repetition of their finding in two large studies indicates the need for further investigation into possible mechanisms.
Two other articles were published on this study of NutraIngredients that contradict the claims made in this study. You can find them by clicking here and here..
Sources: Journal of the National Cancer Institute
Published online before going to press, doi: 10.1093 / jnci / djt174
“Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Study”
Authors: Theodore M. Brasky, Amy K. Darke, Xiaoling Song et al